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Polycystic Ovary SyndromeAbstract Background: Polycystic Ovary Syndrome (PCOS) is clinically associated with infertility.
Many women are resistant to Clomiphene Citrate and the addition of insulin sensitisers may help to
overcome this challenge.
Objective: This review aims to assess if Metformin added to Clomiphene Citrate improves preg-
nancy outcomes in patients with PCOS and are resistant to Clomiphene Citrate.
Search strategy: A systematic search was conducted on four electronic databases published until
May 2013.
Selection criteria: Studies evaluating the use of Metformin in combination with Clomiphene Cit-
rate resistant patients with PCOS compared to placebo. Outcomes assessed were ovulation rate,
pregnancy by ultrasound, Sex Hormone Binding Globulin (SHBG), BMI, fasting insulin and testos-
terone levels.
Data collection and analysis: The reviewers carried out data extraction of speciﬁc outcomes and
evaluated each study according to the sign guidelines.
82 S. Gill et al.Main results: In total 40 citations were identiﬁed however only four were eligible for analysis.
Two studies were found to have a statistically signiﬁcant improvement in ovulation and pregnancy
rates in the intervention group compared to the control group. These studies used the highest dose
of Metformin and Clomiphene Citrate. In two studies we found statistically signiﬁcant reductions in
testosterone concentrations and BMI values.
Authors’ conclusions: Metformin and Clomiphene Citrate have been shown to improve ovulation
and pregnancy rates in the treatment of infertile patients with PCOS who are Clomiphene resistant.
However, the optimal treatment regime remains ambiguous and needs further investigation with
larger sample sizes of adequate power.
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1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
2.1. Literature search. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
2.2. Inclusion criteria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
2.2.1. Type of studies and study population. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
2.2.2. Intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
2.2.3. Outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
2.3. Exclusion criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
2.3.1. Quality assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
2.3.2. Management of the literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.1. Quality assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.2. Primary outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 853.2.1. Ovulation rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.2.2. Pregnancy rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.3. Secondary outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.3.1. Hormonal concentrations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3.4.1. Anthropometric measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4.1. Main ﬁndings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4.2. Strengths and limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
4.3. Interpretation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
5. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Contribution to authorship . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Details of ethics approval . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Conﬂict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 881. Introduction
Infertility is a global problem affecting 48.5 million couples (1) and
is deﬁned as ‘‘a woman of reproductive age who has not conceived
after 1 year of regular unprotected vaginal sexual intercourse’’ (2).
The main causes include ovulatory and uterine disorders,
tubal damage and idiopathic (2). PCOS is an ovulatory disor-
der and is the most common cause of female infertility in UK
affecting 5–10% of patients of reproductive age (3).
Three main patho-physiological features of PCOS are:
polycystic ovaries, anovulation and hyperandrogenism (3).
These lead to clinical features including amenorrhoea/oligom-
enorrhoea, hirsutism and acne (4). However, a third of patients
are asymptomatic (5). Biochemical disturbances include:hyperinsulinaemia, raised Lutenising Hormone (LH) and
hyperandrogenism (6).
Hyperinsulinaemia, insulin resistance and increased androgen
secretion may play a role in the pathogenesis of PCOS induced
infertility (7). Insulin resistance indirectly causes anovulation
through compensatory hyperinsulinaemia (8). Furthermore insu-
lin directly effects ovarian androgen production. Therefore man-
aging insulin resistance may be crucial to fertility treatment (4).
Negative feedback between Sex Hormone-Binding Globu-
lin (SHBG) and fasting insulin suggest SHBG production is
inhibited by insulin (8). Low SHBG concentrations lead to
an increase in the bioactivity of testosterone resulting in hyper-
androgenism. Thus, insulin resistance has a signiﬁcant role in
the pathogenesis and clinical manifestations of PCOS (8).
Metformin combined with Clomiphene Citrate in PCOS women 83Disturbance of the hypothalamic–pituitary–ovarian axis is
an external factor leading to ovarian dysfunction (9). This dis-
turbance leads to increased Gonadotrophin Releasing Hor-
mone (GnRH) resulting in hypersecretion of LH. This
overexpression effects ovarian androgen production and
oocyte development (9).
Other factors include lifestyle, nutrition and genetic
abnormalities (9). Approximately half of patients with PCOS
are overweight, and a third may develop type 2 diabetes
(10).
The ﬁrst line pharmacological treatment for infertility is
Clomiphene Citrate which stimulates ovulation in 70–90%
and pregnancy rates of 30–40% (11–13). However, evidence
dictates 25% are unresponsive, described as Clomiphene Cit-
rate resistance (14). It has recently become associated with
insulin resistance.
In Clomiphene Citrate resistant woman, the standard treat-
ment is gonadotrophins. However, these have increased risk of
multiple pregnancies (14). Therefore, a safer treatment option
is needed.
Previous studies reveal that Metformin administration
reduces ovarian production of androgens, leading to spontane-
ous or Clomiphene Citrate induced ovulation, independent of
Body Mass Index (BMI) changes (4). Insulin sensitisers
decrease gluconeogenesis and utilisation of glucose in the pres-
ence of insulin (15). Therefore, using an insulin sensitiser such
as Metformin may improve metabolic abnormalities and ovu-
lation (7,16–19).Medline = 10 
Embase = 6 
AMED = 0 
Scopus = 24 
Total = 40
Rejected due to 
title
Rejected at 
abstract
19 Abstracts read 
7 Studies read 
Rejected at full 
text
5 Studies for data 
extraction 
Rejected at full 
text
4 Studies 
Analysed 
Figure 1 Flow diagramThe aim of this review is to assess if Metformin alters hor-
mone levels, ovulation rates and pregnancy compared to pla-
cebo in Clomiphene Citrate resistant PCOS patients.
2. Methods
2.1. Literature search
Four electronic bibliographic databases were searched (Med-
line, Embase, AMED and Scopus) from 1946 (AMED 1985,
Scopus 1960, 1947 Embase) until May 2013. The following
terms were used as MeSH and mapping terms: Infertility,
anovulation, randomised control trial, Polycystic Ovary Syn-
drome, PCOS, Metformin, Clomiphene resistance. These
terms were all combined appropriately using the Boolean
operators AND and OR. The search was limited to full text,
English language and female humans (See Fig. 1).
2.2. Inclusion criteria
2.2.1. Type of studies and study population
All randomised controlled trials that involved patients of
reproductive age ranging from 18 to 45 years of age who had
been diagnosed with PCOS were included in the review. In
addition, studies should include patients who had previous
unsuccessful attempts with primary or secondary infertility
treatment and also be Clomiphene resistant.21 were rejected: 
• Compared lifestyle or surgical 
interventions(4)
• Women not resistant to Clomiphene(16) 
• Foreign Language (1) 
12 were rejected: 
• Duplicate studies(6) 
• Insulin sensitising drugs other than 
metformin (6) 
2 were rejected: 
• Not RCT (1) 
• Outcome not ovulation (1) 
1 was rejected: 
• Compared gonadotrophin to metformin 
treatment
of literature search.
84 S. Gill et al.2.2.2. Intervention
All randomised controlled trials or clinical controlled trials
that assessed Metformin against placebo and/or in combina-
tion with Clomiphene Citrate were included in the review.
2.2.3. Outcomes
Primary outcome measures assessed included ovulation rate
and pregnancy by ultrasound. Secondary outcomes included
SHBG, BMI, fasting insulin and testosterone.
2.3. Exclusion criteria
Firstly, studies involving surgical options with regard to treat-
ment of infertility were excluded. Secondly, studies focusing on
lifestyle interventions were excluded. Any studies that con-
tained different combinations of insulin sensitising drugs used
for treatment of infertility were excluded. Reviews and meta-
analyses were excluded for analysis for this review.
2.3.1. Quality assessment
Studies were initially appraised using the SIGN guidelines
(Scottish Intercollegiate Guidelines Network, UK). Scores
out of ten were allocated to each paper using the checklist of
questions in the SIGN guidelines.
2.3.2. Management of the literature
All identiﬁed citations were scanned by titles and abstracts for
relevant studies. Full texts of all potential eligible studies were
obtained and critically appraised by two authors. Studies that
complied with the a priori inclusion and exclusion criteria were
included in the review. Any discrepancies were discussed and
decisions were made about inclusion.
3. Results
Search of the four databases yielded 40 citations. Following the
scanning of abstracts, full texts of ten potentially eligible studiesTable 1 Study characteristics for 4 studies comparing placebo vs M
Author Sample size Ou
Pr
Vandermolen et al., (USA) (22) 27 (2)a Ov
Pr
Ng et al., (China) (21) 20 (2)a Ov
Pr
Kocak et al., (Turkey) (20) 56 (1)a Ov
Pr
Sturrock et al., (UK) (23) 26 ()b Ov
Pr
a Attrition number.
b Unable to determine.were obtained and critically appraised and ﬁnally four studies
that fulﬁlled the criteria were included in this review. The basic
study characteristics are presented in Table 1. All four studies
wereRCTsdating from2001 to2002 carried outworldwide. Sam-
ple sizes varied between studies with 56 participants being the
largest cohort by Kocak et al. (20). Ng et al. recorded the lowest
number of participants with 20 patients (21). After these inclu-
sions there were 129 patients in this review between the 4 studies.
The inclusion criteria were similar between studies, with a
diagnosis of PCOS, Clomiphene Citrate resistance and infertil-
ity being essential. In addition, several studies included further
selection criteria. Vandermolen et al. included oligoovulation,
hyperandrogenism and tubal patency in their inclusion criteria
(22). Sturrock et al. and Ng et al. recruitment criteria sought
patients less than 40 years of age, with PCOS, who were Clo-
miphene Citrate resistant and anovulatory (23,21).
The exclusion criteria varied between studies. In the study
conducted by Vandermolen et al., patients younger than
18 years and those older than 35 years were excluded. Diabetes
mellitus was another exclusion criteria (22). Kocak et al. also
excluded patients with diabetes mellitus (20). Smokers, male
infertility and those with renal impairment were excluded by
Ng et al. (21). In the UK study by Sturrock et al. exclusion cri-
teria were not identiﬁable from the published article (23).
The duration included time from enrolment into the study
until completion of the intervention. The shortest duration
was reported byKocak et al. which lasted twomonths (20). Stur-
rock et al. had the longest study duration of 13 months (23).
The study design was standard among all trials. Two
groups were assessed within each study. Groups consisted of
a placebo plus Clomiphene Citrate arm versus a Metformin
plus Clomiphene Citrate intervention arm.
3.1. Quality assessment
Vandermolen et al., Ng et al., and Kocak et al., are classiﬁed as
high quality papers as they fulﬁlled the majority of theetformin and Clomiphene Citrate.
tcomes
imary Secondary
ulation
egnancy
 Hormone responses and biochemical milieu
 BMI
 Fasting insulin
 SHBG
ulation
egnancy
 Hormone responses and biochemical milieu
 BMI
 Fasting insulin
 Testosterone
 SHBG
ulation
egnancy
 Hormone responses and biochemical milieu
 BMI
 Fasting insulin
 Testosterone
ulation
egnancy
 Hormone responses and biochemical milieu
 BMI
 Fasting Insulin
 Testosterone
 SHBG
Metformin combined with Clomiphene Citrate in PCOS women 85assessment criteria scoring 8/8 (20–22). Whereas, Sturrock
et al. was graded as a poor quality paper due to a lack of trans-
parency with regard to the randomisation method, study
design and statistical analysis used and scored 6/8 (23). The
author of this paper was contacted for clariﬁcation on these
issues, but was unable to elucidate these points.
3.2. Primary outcomes
3.2.1. Ovulation rates
All studies found an improvement in ovulatory rates as a pri-
mary outcome. (See Table 2) In the study by Vandermolen
et al., baseline ovulatory rates for patients receiving placebo
and Clomiphene Citrate were 27%. This increased to 75% in
the intervention group who received Metformin in combina-
tion with Clomiphene Citrate (22). Similarly, Kocak et al.
showed a ﬁvefold increase in ovulatory rates between their
control and intervention groups (20). These 2 studies showed
statistically signiﬁcant ﬁndings.
Further positive ﬁndings were described by Sturrock et al.
where an improvement from 28.5% to 41.6% was observed
between groups (23). However, these ﬁndings were not statisti-
cally signiﬁcant.
Contrasting these positive ﬁndings, Ng et al. reported
higher ovulation rates within their control cohort who received
placebo and Clomiphene Citrate (70%) as opposed to those
receiving Metformin and Clomiphene Citrate (40%). How-
ever, this conclusion cannot be veriﬁed as the statistical signif-
icance has not been reported (21).
3.2.2. Pregnancy rates
Pregnancy rates improved between the control and interven-
tion groups in the same two studies that also reported statisti-
cally signiﬁcant improvements in ovulation rates.
Vandermolen et al. showed an improvement from 7% to
55% following treatment with Metformin and Clomiphene
Citrate (22). Four patients conceived while receiving Metfor-
min and Clomiphene Citrate within the study conducted by
Kocak et al. (20). This contrasted with the control group,
where no patients became pregnant while receiving the placeboTable 2 Primary outcomes.
Author Ovulation
Control I
Vandermolen et al., (USA) (22) N= 4/15
(27%)a
N
(
P
Ng et al., (China) (21) N= 7/10
(70%)
N
P
Kocak et al., (Turkey) (20) N= 4/28
(14.2%)a
N
(
P
Sturrock et al., (UK) (23) N= 4/14
(28%)
N
(
P
NR=Not reported.
a Statistically signiﬁcant.and Clomiphene Citrate. Sturrock et al. reported an increase in
pregnancy rates of 14.2% in the control group compared to
25% within the intervention group. However, these results
were not statistically signiﬁcant (23) (see Table 2).
Ng et al. contradicts the other studies stating an increase in
pregnancy rates following the use of Metformin and Clomi-
phene Citrate in the control group. Two patients became preg-
nant within the control group compared with one pregnancy
within the intervention group (21).
3.3. Secondary outcomes
3.3.1. Hormonal concentrations
While many different hormonal parameters were evaluated in
these studies, four main variables were selected, due to consis-
tency between studies, for analysis: testosterone, fasting insu-
lin, BMI and SHBG (See Table 3). Three studies recorded
changes in testosterone concentrations following treatment
(21–23), of which two were statistically signiﬁcant (20,23).
Two studies noted a reduction in fasting insulin levels in
patients receiving Metformin and Clomiphene Citrate. How-
ever, these reductions were not of statistical signiﬁcance
(20,21). SHBG concentrations were recorded in three trials.
Of these, two reported a reduction in SHBG levels within both
the control and intervention arms post treatment (21,22).
However, these ﬁndings were not statistically signiﬁcant. Stur-
rock et al. was the only study that found increased concentra-
tions of this hormone following treatment with Metformin and
Clomiphene Citrate (23).
3.4.1. Anthropometric measures
Each study found a reduction in BMI measurements follow-
ing treatment with Metformin and Clomiphene Citrate,
however, two studies reported a statistically signiﬁcant reduc-
tion in BMI in the intervention group compared to the con-
trol group (20,21). Ng et al. recorded a baseline BMI value of
24.1, which dropped to 23.0 after treatment (P< 0.01) (21).
Similar results are seen in the study by Kocak et al. where
BMI fell from 31.91 ± 5.38 to 30.47 ± 5.25 (P= 0.01) (20)
(see Table 3).Pregnancy
ntervention Control Intervention
= 9/12
75%)a
= 0.02
N= 1/14
(7%)a
N= 6/11
(55%)a
P= 0.02
= 4/10 (40%)
= NR
N= 2/9
(22%)
N= 1/9
(11%)
P=NR
= 21/27
77.7%)a
= 0.001
N= 0
(0%)a
N= 4
(11%)a
P= 0.04
= 5/12
42%)
= 0.63
N= 2/14
(14.2%)
N= 3/12
(25%)
P= 0.59
Table 3 Secondary outcomes.
Author Testosterone Fasting insulin
Control Intervention Control Intervention
Vandermolen et al., (USA) (22) No data No data 12.5 ± 1.9 (pre)
14.4 ± 4.2 (post)
8.9 ± 1.8 (pre)
10.4 ± 2.1 (post)
P= 0.524
Ng et al., (China) (21) 1.3 (pre)a
1.5 (post)a
1.8 (pre)a
1.2 (post)a
P= 0.05
12.1 (pre)
7.3 (post)
10.8 (pre)
8.2 (post)
P=NR
Kocak et al., (Turkey) (20) 1.3 ± 0.6 (pre)a
1.31 ± 0.4 (post)a
1.47 ± 0.84 (pre)a
1.04 ± 0.34 (post)a
P= 0.001
21.3 ± 27.1 (pre)
22.3 ± 29.1 (post)
28.11 ± 36.1 (pre)
21.3 ± 29.7 (post)
P=NR
Sturrock et al., (UK) (23) 0.15b +0.4b
P= 0.17
2.1b +1.5b
P= 0.83
Author BMI SHBG
Control Intervention Control Intervention
Vandermolen et al., (USA) (22) 38.4 ± 2.2 (pre)
38.4 ± 2.0 (post)
37.6 ± 4.3 (pre)
35.4 ± 3.1 (post)
P= 0.146
74 ± 8.3 (pre)
71 ± 9.8 (post)
74 ± 8.3 (pre)
71 ± 9.8 (post)
P= 0.893
Ng et al., (China) (21) 20.7 (pre)a
23.1 (post)a
24.1 (pre)a
23.0 (post)a
P= 0.01
36.6 (pre)
32.9 (post)
28.7 (pre)
26.6 (post)
P=NR
Kocak et al., (Turkey) (20) 30.8 ± 4.4 (pre)a
31.1 ± 3.5 (post)a
31.91 ± 5.38 (pre)a
30.47 ± 5.25 (post)a
P= 0.01
No data No data
Sturrock et al., (UK) (23) +0.1b 1.1b
P= 0.41
+3b +4.5b
P i= 0.29
NR= Not reported.
a Statistically signiﬁcant.
B Not Signiﬁcant unreported by author due to unclear method of statistical analysis.
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4.1. Main ﬁndings
Our systematic review was to assess whether Metformin com-
bined with Clomiphene Citrate improves pregnancy and ovula-
tion rates in PCOS patients who were resistant to Clomiphene
Citrate.
The data suggest the combination of Metformin and Clo-
miphene Citrate may succeed in inducing a higher rate of ovu-
lation (20,22,23). However, this increase does not correlate to a
direct increase in pregnancy rates. A number of mechanisms
can be proposed as having pivotal roles, particularly in refer-
ence to the prolonged exposure of Clomiphene Citrate. Previ-
ous studies have concluded that the repetitive exposure of
Clomiphene Citrate has a deleterious consequence on the
endometrial receptivity to the ovulated follicle, and oocyte
quality (24). These effects may offset the beneﬁcial effects
offered by Metformin therapy.
In addition, the variations observed in pregnancy rates
may be attributed to the study designs. The dose regime
and treatment duration of Metformin and Clomiphene Cit-
rate may account for the variabilities observed. Interestingly,
the study design with the smallest number of participants
recorded no increase in either ovulation or pregnancy rates
under the treatment arms (21). These results suggest that
studies using the higher concentrations of Metformin and
Clomiphene Citrate over an extended period may yield the
most positive effects.As impaired ovulation is thought to be linked to insulin
resistance, the potential beneﬁts of Metformin could be attrib-
uted to an increase in insulin sensitivity, therefore improving
ovulation rates (25). Research has shown that use of insulin-
sensitising agents within a non-diabetic cohort reduces insulin
levels, while blood glucose levels remain unaffected (26). Stud-
ies within the conﬁnes of this review attested that Metformin
targets hyperinsulinaemia associated with PCOS. Therefore,
it can be postulated that this mechanism is the basis on which
positive results were observed in these studies.
In order to achieve a valid comparison, all of the patients
who were included in these studies had previously failed to
achieve pregnancy using Clomiphene Citrate only. Clomiphene
Citrate resistance was deﬁned in all studies as a failure to ovu-
late to a dose schedule of 150 mg/day for 5 days during three
consecutive menstrual cycles (27). The Clomiphene Citrate
cut-off dose was 50–200 mg/day in all studies. Consequently,
this target population was standardised across all studies –
adding validity to the comparisons concluded.
Testosterone levels were the only statistically signiﬁcant
reduction reported in the hormonal parameters (20,21). How-
ever, the clinical signiﬁcance of a reduction in any of the hor-
monal parameters under evaluation remains debatable (28). As
increased testosterone levels are thought to impair folliculo-
genesis (25), a reduction in this parameter may improve ovula-
tion and pregnancy rates.
Insulin stimulates the synthesis of androgens within the
ovary (25). Metformin acts as an insulin sensitiser thereby
reducing testosterone concentrations. Kocak et al., reported
Metformin combined with Clomiphene Citrate in PCOS women 87an almost 30% reduction in testosterone levels in patients
receiving Metformin and Clomiphene Citrate (20). As the
pre-treatment group showed no changes in testosterone levels,
this reduction could be solely attributed to Metformin. Ng
et al. also reported a statistically signiﬁcant reduction in testos-
terone levels in their intervention arm (21). These studies rein-
force the potential beneﬁt of Metformin in reducing this
parameter.
A reduction in BMI was of statistical signiﬁcance in the
same two studies that also found a reduction in testosterone
levels (20,21). While Ng et al. recorded a statistically signiﬁcant
reduction in BMI values in the intervention arm, their baseline
values for BMI were the lowest of all the studies (21). Addi-
tionally, in spite of this reduction, this study did not show
an improvement in ovulation and pregnancy rates following
interventional treatment.
The beneﬁts of Metformin observed in this study are
regarded as a consequence of increased insulin sensitivity.
Studies have provided supporting evidence to this theory, by
assessing the endocrine proﬁles of non-diabetic patients with
PCOS treated with Metformin (18,24). Conformation of this
fact could be explored further by the direct assessment of insu-
lin sensitivity.
4.2. Strengths and limitations
There were many strengths of this review beginning with
the thorough and concise search method utilised in the
preparation. This ensured that the RCTs selected for review
clearly addressed the aims and objectives within our
research question. Of the four trials selected, three were
assessed as being of high quality (20,21). One study was
assessed as being of poor quality, but was included in this
review to ensure completeness of the current literature in
this ﬁeld (23).
Despite a robust search in four databases there are numer-
ous limitations in this review. It is worth highlighting the lack
of published RCTs in this research ﬁeld and could be strength-
ened with the support of further trials. Larger sample sizes are
also needed to add power to the results obtained and to pro-
vide a more representative overview of this intervention. The
most recent trial conducted in 2002 highlighted the need for
more research in this area.
The doses of Metformin and Clomiphene Citrate varied
between studies, as did their duration, thus being ineligible
for a meta-analysis. Discrepancies reported within the primary
and secondary outcomes may be due to such disparities.
Therefore, further RCTs using similar doses and durations
of treatment are essential to conclude if the beneﬁts can be
attributed to a speciﬁc treatment regime.
A distinct lack of follow-up and monitoring was observed
throughout all trials. This review would beneﬁt from a fol-
low-up period with details of monitoring protocols. This is
important when assessing changes within hormonal concentra-
tions and anthropometric measures, as these may not be fully
evident within the current study durations.
Only papers written in the English language were
selected, omitting potentially eligible articles. Important
issues including the frequency of coital practices were also
not included.4.3. Interpretation
It is important to consider that while assessing the outcomes
of this review, a lack of statistical signiﬁcance does not corre-
late with a lack of clinical signiﬁcance. The intervention arm
in Vandermolen et al. demonstrated a reduced BMI value fol-
lowing treatment, but it was not of statistical signiﬁcance
(22). However, a reduced BMI could play an important role
in fertility treatment. This is also true of the hormonal
parameters that were assessed such as fasting insulin concen-
trations (29).
While the beneﬁts of Metformin and Clomiphene Citrate
treatment in improving ovulation and pregnancy rates have
been highlighted, it is important to consider the practicalities
of this intervention. In relation to Metformin, side effects were
observed throughout the trials including nausea and vomiting
(21). Another practical issue is the time consuming nature of
this intervention, particularly when a more rapid fertility treat-
ment option may be necessary in elderly patients (25).
The standard second line treatment option for Clomiphene
Citrate resistant patients is gonadotrophin therapy. By utilis-
ing Metformin and Clomiphene Citrate, this could provide
an alternative treatment option prior to progressing to gonad-
otrophin therapy. This could be beneﬁcial to patients due to
the substantial costs of this therapy and undesirable adminis-
tration via injection (25).
5. Conclusion
These results suggest that the dose combination and duration
of exposure to Metformin and Clomiphene Citrate may play
a pivotal role in determining the effectiveness of this interven-
tion. While this systematic review is limited by the number of
RCTs available, overall it presents a positive portrayal for
the use of Metformin as an adjunct to Clomiphene Citrate
for Clomiphene Citrate resistant patients. Further research
using a larger sample size is required to identify the optimal
dosage and duration of this intervention. More recent trials
would be desirable to further consolidate these scientiﬁc
results.
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